Company Name, Ticker, Competitors, else..

Regenicin Inc (RGIN)

Sector • Healthcare Industry • Medical Equipment & Supplies

Industry • Medical Equipment & Supplies

Sector • Healthcare

Regenicin Inc 's

Name: Regenicin Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RGIN Sales vs. its Competitors Q2 2023

Comparing the current results to its competitors, Regenicin Inc reported Revenue decrease in the 2 quarter 2023 year on year by 0 %, slower than the combined decrease of the RGIN's competitors by -27.5 %, recorded in the same quarter.

• List of RGIN Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Regenicin Inc , slower than the average decrease reported by the company's competitors of -37.66 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -37.66 %

<< RGIN Stock Performance Comparisons

<< See the full list of RGIN competitors

*Market share is calculated based on total revenue.

RGIN's Stock Performance relative to its Competitors

Publicly Traded Peers of Regenicin Inc

Better Therapeutics Inc
Share Performance

0.00%

This Year

Better Therapeutics Inc

Profile

Better Therapeutics Inc is a digital therapeutics company that combines evidenced-based clinical interventions with software technology to address chronic diseases. Their business model revolves around developing and delivering prescription software applications to patients, which are meant to be used alongside pharmaceutical therapies. Their aim is to provide personalized and scalable solutions that have the potential to improve health outcomes and reduce healthcare costs.

More about Better Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 0.004 mill.	$ - mill.	$ -31.573 mill.

Euda Health Holdings Limited
Share Performance

-14.99%

This Quarter

Euda Health Holdings Limited

Profile

Euda Health Holdings Limited operates as a digital health platform that facilitates access to healthcare services. They offer a range of online health consultations and concierge services, enabling users to connect with healthcare professionals and receive personalized medical advice and treatment. Their business model focuses on leveraging technology to streamline the healthcare experience and improve access to quality care for individuals seeking medical assistance.

More about Euda Health Holdings Limited's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1.257 mill.	$ 5.993 mill.	$ -2.768 mill.

Amgen Inc
Share Performance

+37.04%

One Year

Amgen Inc

Profile

Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.

More about Amgen Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 206,053.600 mill.	$ 38,095.000 mill.	$ 8,743.000 mill.

Bioplus Acquisition Corp
Share Performance

+1.89%

This Quarter

Bioplus Acquisition Corp

Profile

Bioplus Acquisition Corp's business model focuses on acquiring and merging with companies in the biotechnology industry, with the aim of enhancing value for its shareholders.

More about Bioplus Acquisition Corp 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 221.826 mill.	$ - mill.	$ 5.795 mill.

Crispr Therapeutics Ag
Share Performance

-2.75%

This Year

Crispr Therapeutics Ag

Profile

CRISPR Therapeutics AG is a biopharmaceutical company focused on developing transformative gene-based medicines using its CRISPR/Cas9 gene-editing platform. They aim to leverage the potential of CRISPR to treat severe genetic diseases by directly modifying genes within the body's cells. The company collaborates with partners, conducts research and development of their therapeutics, and ultimately aims to bring their innovative treatments to market.

More about Crispr Therapeutics Ag's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 5,046.722 mill.	$ 13.392 mill.	$ -451.139 mill.

2 more competitors available

Sources: Regenicin Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Sunday, September 13, 2026 11:23 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Regenicin Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.